Clarivate

MAY 14, 2024

The company filed for marketing approval of their semaglutide biosimilar for the treatment of T2D with the National Medical Products Administration (NMPA) in April 2024, and this is expected to amplify clinical development of semaglutide biosimilars from domestic manufacturers in the next two to three years.

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

PM360

SEPTEMBER 30, 2024

This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.

Networking 52

Networking Healthcare Healthcare Competition 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

European Pharmaceutical Review

NOVEMBER 30, 2023

Licensing of the manufacturing suites is expected in early 2024. NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

European Pharmaceutical Review

OCTOBER 8, 2024

CPHI Milan, the premier international pharmaceutical event, will be held from 8 to 10 October 2024 at Fiera Milano, Italy. The event is a key platform for global supply chain connections, offering unmatched opportunities to form partnerships, secure contracts, and stay competitive.

Pharma 52

Pharma Manufacturing Pharmaceutical Management 52

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.

Competition 52

Competition Leads Patients Marketing 52

Clarivate

AUGUST 7, 2024

The three largest pharmacy benefit managers (PBMs) in the United States—Express Scripts, OptumRx and CVS Caremark—control more than 80% of the market share (per Clarivate data, as of January 2024). Click here to learn more about how Clarivate helps biopharma companies navigate market access across global markets.

Retail 59

Retail Marketing Biopharma Competition 59

Clarivate

MAY 8, 2024

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. Other partnerships of note include one for a couple of Shanghai-based Elpiscience Biopharma Ltd’s preclinical bispecific antibody assets, licensed by Tokyo-based Astellas Pharma Inc, with the option to license two more.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

AUGUST 20, 2024

Announced on August 15, 2024, this first batch of Maximum Fair Prices (MFPs) were mandated by the Inflation Reduction Act of 2022 , which allowed CMS to negotiate what it describes as the maximum fair price for therapies representing the greatest cost to Medicare.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Pharmaceutical Technology

MAY 22, 2023

The ongoing patent litigation between CureVac and Pfizer /BioNTech will move to a court in Virginia following a request from Curevac, potentially bringing forward the trial date to sometime in 2024. The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly.

Biopharma 116

Biopharma Prospecting Competition Pharmaceutical 116

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. In December 2022, AEON Biopharma announced plans to go public through a merger with the SPAC Priveterra Acquisition Corp. But such areas are highly competitive.

Marketing 69

Marketing Biopharma Pharma Competition 69

Clarivate

DECEMBER 14, 2023

Pharmaceutical benefit managers, M&A activity among integrated delivery networks, disruption by nontraditional healthcare entities, enrollment, and the 2024 presidential election are five areas to pay attention to moving into 2024. Clarivate experts explain why these topics are ones to watch in 2024.

Marketing 52

Marketing Healthcare Healthcare Insurance 52

Clarivate

OCTOBER 17, 2024

Congressional Democrats introduced legislation to make the subsidies permanent in September 2024, but the legislation has no chance of passage so close to the election. 31, 2024, and providers and payers are pushing for an extension. Loss of subsidies could cause spikes in insurance premiums and major losses in exchange enrolment.

Healthcare 52

Healthcare Healthcare Government Insurance 52